Coadministration of tenofovir disoproxil fumarate (300 mg once daily) and elbasvir alone (50 mg once daily, n=10), grazoprevir alone (200 mg once daily, n=12), or elbasvir/grazoprevir (50/100 mg once daily, n=13) was studied in HIV/HCV-negative subjects. Elbasvir AUC, Cmax and C24 all decreased by ~10%; grazoprevir AUC, Cmax and C24 decreased by ~10%, ~20% and ~10% respectively. Tenofovir AUC and Cmax and C24 increased by 34%, 47% and ~30% with elbasvir alone and by 18%, 14% and ~20% with grazoprevir alone; administration with elbasvir/grazoprevir increased tenofovir AUC, Cmax and C24 by 27%, 14% and ~20%, respectively. No dose adjustments for elbasvir/grazoprevir or tenofovir-DF are needed for coadministration in HCV/HIV-coinfected people.
Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate. Feng HP, Guo Z, Caro L, et al. Clin Pharmacol Drug Dev, 2019, 8(7):962-970.